Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | STK4 | Q13043 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430194 | 1.00 | RET (0.41) | RETCNR1CNR2STK4ROCK1 | |
| SCHEMBL12231886 | 0.90 | STK4 (0.43) | RETCNR1CNR2STK4ROCK1 | |
| SCHEMBL2374837 | 0.89 | IKBKB (0.49) | ROCK1IKBKBCCNT1CCNA2CDK2 | |
| SCHEMBL12255951 | 0.89 | CNR1 (0.50) | CNR1CNR2STK4ALDH1A1NPY5R | |
| SCHEMBL12231911 | 0.88 | ROCK1 (0.47) | CNR1CNR2STK4ROCK1IKBKB | |
| SCHEMBL2374300 | 0.87 | SYK (0.42) | STK4ROCK1HSD17B10JAK2ALDH1A1 | |
| SCHEMBL31681850 | 0.87 | SYK (0.42) | STK4ROCK1HSD17B10JAK2ALDH1A1 | |
| SCHEMBL2375240 | 0.87 | KMT2A (0.44) | ROCK1IKBKBCDK2PDGFRBSRC | |
| SCHEMBL2373916 | 0.86 | ROCK1 (0.43) | ROCK1KDM4ECDK2 | |
| SCHEMBL12231898 | 0.85 | NAMPT (0.41) | ROCK1IKBKBCDK2ALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | FATE THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4692319-A1 | METHOD FOR PRODUCING RETINAL TISSUE | RACTHERA Co., Ltd. (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260028593-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ANTIBODY-GENERATING IMMUNE ORGANOIDS | PARALLEL BIOSYSTEMS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260028588-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | UMOJA BIOPHARMA, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-20110294761-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294761-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-01 | — | — | US | disclosed |
| US-8044201-B2 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044201-B2 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044201-B2 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110224233-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224233-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224233-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2011047300-A1 | INDUCTION OF PLURIPOTENT CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010065721-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | GSK3B, GSK3A, WNT3A | RET 1873/4885CNR1 4835/4885CNR2 4820/4885 |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | RET 2244/4885CNR1 701/4885CNR2 1497/4885 |
| US-20260028588-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | BMP4, FLT4, FGF2 | RET 762/4885CNR1 4596/4885CNR2 4089/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | RET 2354/4885CNR1 3846/4885CNR2 2405/4885 |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | WNT3A, FGF2, MEF2D | RET 697/4885CNR1 3840/4885CNR2 4160/4885 |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | KIT, FLT1, HGF | RET 614/4885CNR1 4459/4885CNR2 4469/4885 |
| US-20110294761-A1 | STEM CELL CULTURES | NES, CD44, MCL1 | RET 4691/4885CNR1 3805/4885CNR2 3926/4885 |
| US-20260028593-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ANTIBODY-GENERATING IMMUNE ORGANOIDS | CD22, CD2, CD40LG | RET 1175/4885CNR1 3853/4885CNR2 3947/4885 |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD14, HGF | RET 771/4885CNR1 4808/4885CNR2 4739/4885 |
| US-20110224233-A1 | STEM CELL CULTURES | NES, CD44, MCL1 | RET 4691/4885CNR1 3805/4885CNR2 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.